Tuesday, September 27, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., completed patient enrollment in its second randomized Phase II trial for bavituximab. The company said 66 patients with previously untreated genotype-1 hepatitis C virus infection were treated with 12 weeks of ribavirin in combination with bavituximab or pegylated interferon alpha-2a.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.